Risperidone Treatment in Children and Adolescents with Autism: Short- and Long-Term Safety and Effectiveness

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 41, Issue 2, 2002, Pages 140-147

  Malone, Richard P ^a,d   Maislin, Greg ^b   Choudhury, Muniya S ^c   Gifford, Cynthia ^a   Delaney, Mary Anne ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Biomedical Statistical Consulting   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d Eastern Pennsylvania Psychiat Inst   (United States)

Author keywords

Dyskinesia; Neuroleptics; Pervasive developmental disorder

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; RISPERIDONE; NEUROLEPTIC AGENT;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADOLESCENT; APPETITE DISORDER; ARTICLE; AUTISM; BODY WEIGHT DISORDER; CHILD; CHILDRENS PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DEVELOPMENTAL DISORDER; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; FEMALE; HUMAN; LONG TERM CARE; MALE; OPEN STUDY; PRIORITY JOURNAL; RATING SCALE; SEDATION; SHORT COURSE THERAPY; SIDE EFFECT; WEIGHT GAIN; WITHDRAWAL SYNDROME; ANALYSIS OF VARIANCE; TIME;

ADOLESCENT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; DYSKINESIA, DRUG-INDUCED; HUMANS; RISPERIDONE; TIME FACTORS;

EID: 0036479943     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-200202000-00007     Document Type: Article

References (37)

1. American Psychiatric Association (1994), Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Association
2. Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J (1989), The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 19:227-239
3. Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH (1984), Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 141:1195-1202
4. Armenteros JL, Whitaker AH, Welikson M, Stedge DJ, Gorman J (1997), Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry 36:694-700
5. Campbell M, Adams P, Perry R, Spencer EK, Overall JE (1988a), Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol Bull 24:251-255
6. Campbell M, Adams P, Small AM et al. (1988b), Efficacy and safety of fenfluramine in autistic children. J Am Acad Child Adolesc Psychiatry 27:434-439
7. Campbell M, Anderson LT, Meier M et al. (1978), A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 17:640-655
8. Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M (1993), Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 32:1283-1291
9. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE (1997), Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 36:835-843
10. Campbell M, Malone R, Kafantaris V (1990), Autism and aggression. In Treatment Strategies in Child and Adolescent Psychiatry, Simeon JG, Ferguson HB, eds. New York: Plenum, pp 77-98
11. Campbell M, Palij M (1985), Behavioral and cognitive measures used in psychopharmacological studies of infantile autism. Psychopharmacol Bull 21:1047-1053
12. Campbell M, Rapoport JL, Simpson GM (1999), Antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 38:537-545
13. Campbell M, Schopler E, Cueva JE, Hallin A (1996), Treatment of autistic disorder. J Am Acad Child Adolesc Psychiatry 35:134-143
14. Cohen IL, Campbell M, Posner D, Small AM, Triebel D, Anderson LT (1980), Behavioral effects of haloperidol in young autistic children: an objective analysis using a within-subjects reversal design. J Am Acad Child Psychiatry 19:665-677
15. Demb HB (1996), Risperidone in young children with pervasive developmental disorders and other developmental disabilities (letter). J Child Adolesc Psychopharmacol 6:79-80
16. Ernst M, Malone RP, Rowan AB, George R, Gonzalez NM, Silva RR (1999), Antipsychotics (neuroleptics). In: Practitioner's Guide to Psychoactive Drugs for Children and Adolescents, 2nd ed, Werry JS, Aman MG, eds. New York: Plenum, pp 297-328
17. Findling RL, Maxwell K, Wiznitzer M (1997), An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 33:155-159
18. Fisman S, Steele M (1996), Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol 6:177-190
19. Hardan A, Johnson K, Johnson C, Hrecznyj B (1996), Case study: risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry 35:1551-1556
20. Horrigan J, Barnhill L (1997), Risperidone and explosive, aggressive autism. J Autism Dev Disord 27:313-323
21. Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM (1998), Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 8:151-159
22. Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA (2001), Olanzapine vs. haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 40:887-894
23. Malone RP, Ernst M, Godfrey KA, Locascio JJ, Campbell M (1991), Repeated episodes of neuroleptic-related dyskinesias in autistic children. Psychopharmacol Bull 27:113-117
24. Malone RP, Sheikh R, Zito JM (1999), Novel antipsychotic medications in the treatment of children and adolescents. Psychiatr Serv 50:171-174
25. Martin A, Koenig K, Scahill L, Bregman J (1999), Open-labeled quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 9:99-107
26. McDougle CJ, Holmes JP, Bronson MR et al. (1997), Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 36:685-693
27. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH (1998), A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55:633-641
28. McDougle CJ, Scahill L, McCracken JT et al. (2000), Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am 9:201-224
29. Naruse H, Nagahata M, Nakane Y, Shirahashi K, Takesada M, Yamazaki K (1982), A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiatr 48:173-184
30. National Institute of Mental Health (1985), Special feature: rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 21(4):713-1125
31. Nicolson R, Awad G, Sloman L (1998), An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 37:372-376
32. Overall JE, Campbell M (1988), Behavioral assessment of psychopathology in children: infantile autism. J Clin Psychol 44:708-716
33. Perry R, Campbell M, Adams P et al. (1989), Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 28:87-92
34. Perry R, Pataki C, Munoz-Silva DM, Armenteros J, Silva RR (1997), Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J Child Adolesc Psychopharmacol 7:167-179
35. Schooler NR, Kane JM (1982), Research diagnoses for tardive dyskinesia (letter). Arch Gen Psychiatry 39:486-487
36. Wirshing DA, Wirshing WC, Kysar L et al. (1999), Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60:358-363
37. Zuddas A, DiMartino A, Muglia P, Cianchetti C (2000), Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 10:79-90